Fund managers feel concerns about Obama reforms are "overdone," AIC study finds

23 March 2009

The UK's Association of Investment Companies says that a recent survey of fund managers shows that many of them believe the life sciences  sector is under-valued.

The London-based organization, which represents the interests of the  investment trust industry, noted that drugmakers have held up well over  the last year of economic uncertainty, posting a gain of 10%, while  other industries have suffered losses. Over the last three, five and 10  years the sector is down 10%, up 14% and up 168%, respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight